Consent Development

Consent Development

With few waivers and exceptions, researchers must obtain and document prospective consent from the research subject before initiating any screening or study procedures. Any exceptions must be reviewed and approved by the IRB beforehand. 

Consent Form Templates

When developing a consent document, you should start with the appropriate Consent, Assent and Screening Informed Consent forms for your study. With rare exceptions, new consent forms should include all applicable standards language and follow the layout of the consent form templates. These templates include required regulatory elements and UC/UCSD-required language.

Choosing a Consent Form Template

Rather than dividing the templates into biomedical and behavioral templates, they are divided into the templates used for minimal risk studies, greater than minimal risk studies or both. It is important to use the consent template that best fits the type of research you are conducting. For example, if you are conducting a study that involves the use of investigational or approved drugs, devices, diagnostics, therapeutics; or studies that may be considered interventional research, use the Biomedical greater than minimal risk consent form template.

If you are unsure which template to use, please contact the HRPP office.

IRB Guidance for All Research Studies

Documentation of informed consent: Federal and state regulations direct that informed consent be documented, in general, with a written consent form approved in advance by the IRB and incorporating the required elements of consent. The participant or his/her legally authorized representative reads, signs and dates the consent form. The person obtaining consent also signs and dates the consent form. A signed copy of the consent form is given to the participant or, when appropriate, to his/her legally authorized representative. 

Note: No changes may be made to the form without prior approval from the IRB.

The IRB may ask for the inclusion of additional elements of consent that are recommended by the Common Rule, including:

• A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant), which are currently unforeseeable
• Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent
• Any additional costs to the subject that may result from participation in the research
• The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject
• A statement that significant new findings developed during the course of the research, which may relate to the subject's willingness to continue participation, will be provided to the subject
• The approximate number of subjects involved in the study

Please contact the HRPP for questions or study-related issues.